Reclassifying Cannabis as Schedule III: Unpacking the Impact on Taxation, Medical Research, and Social Justice Source: JD Supra On April 30, 2024, the Associated Press reported a significant development in cannabis policy: the U.S. Drug Enforcement Administration...
Boozman Unveils Senate Ag Republicans Farm Bill Framework Senate Committee on Agriculture, Nutrition, and Forestry, released the Senate Republican-drafted framework of the Farm Bill. “Following on the House Committee on Agriculture’s bipartisan passage of...
June 10 2024 Matthew Gurnick Akerman LLP – HR Defense Via JD SUPRA https://www.jdsupra.com/legalnews/california-s-new-drug-testing-rules-2770586/ With expanding legalization and commercialization—including several state initiatives in 2024 and perhaps even federal...
Article: Off-Label Drug Use Liability Julia Englebert Scholar argues that FDA approval should not save drug makers from state-law claims arising from off-label use. A patient walks into her doctor’s office with a headache. She walks out with a prescription for...
As the Drug Enforcement Administration (DEA) moves marijuana from Schedule I to Schedule III, a new pathway for the development of marijuana-based prescription drugs opens. As the Drug Enforcement Administration (DEA) moves marijuana from Schedule I to Schedule III, a...
Article by: Tom Zuber, Janet Jackim, and Jim Ickes The Drug Enforcement Administration (DEA) has recently clarified its stance, indicating that THC-A, a precursor to the psychoactive compound THC, does not qualify as legal hemp under current federal law. This...